Regen-Cov (Intravenous)

Casirivimab和Imdevimab是用于治疗由冠状病毒引起的病症的实验药物。目前尚不清楚，如果casirivimab或imdevimab是安全有效的。

美国食品和药品监督管理局（FDA）已授权在考验Covid-19测试阳性的人的人的紧急使用Casirivimab和Imdevimab，以治疗Covid-19症状，这可能变得足够严重，以便在医院或死亡中需要治疗。

Casirivimab and imdevimab are also for use in people whohave been exposed to COVID-19和:

• 没有完全接种疫苗 - 19;要么
• are vaccinated but may not have built up enough immunity (because they have certain diseases or use certain medicines),和have been or may be exposed to people who are infected with COVID-19.

Casirivimab和Imdevimab用于成人和儿童至少12岁，重量至少88磅（40公斤）。

COVID-19症状的风险severe may be higher in people who:

• 超重;
• have chronic kidney disease;
• have diabetes;
• have a weak immune system (caused by disease or by using certain medicine);
• have sickle cell disease;
• have a heart problem or high blood pressure;
• have a neurodevelopmental disorder such as cerebral palsy;
• have asthma or other chronic breathing disorder; or
• have a tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19).

There also may be a higher risk of severe COVID-19 symptoms在孕妇中和in adults who are 65 and older.

Casirivimab和Imdevimab混合在一起称为一个呼叫的解决方案Regen-Cov.

Casirivimab and imdevimab have not been approved to treat coronavirus or COVID-19.However, these medicines may help prevent the need for emergency medical care or admission to a hospital because of COVID-19.Regen-Covisnot授权用于已经在医院的人或接受Covid-19的补充氧气的人使用。

CasiRivimab和Imdevimab也可用于本药物指南未列出的目的。